➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Harvard Business School
McKinsey
Dow
Colorcon

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LURBINECTEDIN

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Lurbinectedin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01314599 Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome Completed PharmaMar Phase 1 2011-05-01 Phase I Study of PM01183 in Patients with Advanced Acute Leukemia to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183.
NCT01831089 Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Completed PharmaMar Phase 1 2013-09-01 Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors
NCT01951157 A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients Completed PharmaMar Phase 2 2013-10-01 A clinical study of lurbinectedin(PM01183) alone or in combination with gemcitabine in comparison to docetaxel for the treatment of unresectable non-small cell lung cancer (NSCLC)patients
NCT01980667 Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors Recruiting PharmaMar Phase 1 2014-02-01 Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Cisplatin in Patients with Advanced Solid Tumors to determine the recommended dose (RD) of PM01183 in combination with cisplatin, to characterize the safety profile, the pharmacokinetics (PK) of this combination, to obtain preliminary information on the clinical antitumor activity and to conduct an exploratory pharmacogenomic (PGx) analysis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lurbinectedin

Condition Name

Condition Name for Lurbinectedin
Intervention Trials
Ovarian Cancer 2
Advanced Solid Tumors 2
Metastatic Colorectal Cancer 1
Pancreatic Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lurbinectedin
Intervention Trials
Small Cell Lung Carcinoma 3
Lung Neoplasms 3
Carcinoma, Non-Small-Cell Lung 2
Myelodysplastic Syndromes 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lurbinectedin

Trials by Country

Trials by Country for Lurbinectedin
Location Trials
United States 43
Switzerland 3
Spain 2
Belgium 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lurbinectedin
Location Trials
Texas 5
California 4
New York 3
Massachusetts 3
Arizona 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lurbinectedin

Clinical Trial Phase

Clinical Trial Phase for Lurbinectedin
Clinical Trial Phase Trials
Phase 3 2
Phase 2 4
Phase 1/Phase 2 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lurbinectedin
Clinical Trial Phase Trials
Completed 5
Recruiting 5
Active, not recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lurbinectedin

Sponsor Name

Sponsor Name for Lurbinectedin
Sponsor Trials
PharmaMar 11
Massachusetts General Hospital 1
Dana-Farber Cancer Institute 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lurbinectedin
Sponsor Trials
Industry 12
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Merck
Johnson and Johnson
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.